HIV: Roadmaps to a vaccine.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1.eLife · 2022
   Article
2. Detecting Selection in the HIV-1 Genome during Sexual Transmission Events.Viruses · 2022
   Observational
3. Conformational Heterogeneity of the HIV Envelope Glycan Shield.Scientific reports · 2017
   Article
4. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.The Journal of biological chemistry · 2017
   Article
5. Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.CPT: pharmacometrics & systems pharmacology · 2016
   Article
6. Host-Pathogen Coevolution and the Emergence of Broadly Neutralizing Antibodies in Chronic Infections.PLoS genetics · 2016
   Article
7. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.AIDS patient care and STDs · 2016
   Review
8. HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.PloS one · 2016
   Article
9. Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.mBio · 2015
   Article
10. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.Journal of virology · 2014
    Article
11. Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.PloS one · 2014
    Article
12. Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1.Frontiers in immunology · 2014
    Review
13. An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Frontiers in immunology · 2014
    Review
14. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.Vaccines · 2013
    Review
15. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Current opinion in HIV and AIDS · 2013
    Review
16. Development of prophylactic vaccines against HIV-1.Retrovirology · 2013
    Review
17. The role of infection in miscarriage.Human reproduction update
    Review

Corrections and comments

• Comment on
  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as